Where to Buy Epithalon: Four Channels, One Priced per mg

Read the last column first. It is the number each channel declines to publish, and it is usually the number that would decide the comparison.

Three of the four fail on the same point rather than on price. They do not publish a mass you can divide by, so any figure you calculate for them is an estimate you invented. The channel comparison for the neighbouring Russian peptide reaches the same shape for the same reason on our Selank channel page.

This is the only route that hands you a document describing the exact object in the box. On the listing above that document is a Kovera Labs certificate for batch 15-05260628, report KVR-2026-A36FF4, certified 23 May 2026, and it prints five results: purity of 99.312% against a stated minimum of 98% by reversed-phase HPLC with detection at 214 nm, identity confirmed by LC-MS, a net content of 9.64 mg against a specification of 10 mg plus or minus 10 percent, an endotoxin screen passing a 0.5 EU/mL limit, and a sterility screen with no growth. Arsenic, cadmium, lead and mercury all read negative.

The net content row is what makes this channel comparable at all. Everywhere else in this market, cost per milligram is computed from a label, which is a manufacturing target rather than a measurement. Here the denominator was weighed, and it came in under the label:

Publishing that costs the vendor nine cents a milligram in its own advertised rate. It is worth noticing which direction a seller rounds when nobody would have checked, and this one has rounded both ways: its February 2026 Selank certificate measured 12.29 mg in a 10 mg vial, roughly 23 percent over.

Longevity and anti-ageing practices do market this compound, which distinguishes it from most research peptides and is the honest reason people search for a local source. What such a practice sells, though, is not a vial. It is an appointment, an assessment and a prepared preparation, and the invoice reflects that bundle.

The consequence for arithmetic is total. A programme price cannot be divided into dollars per milligram unless the practice tells you the mass it is dispensing and where the material was sourced, and those two facts are rarely on a price list. Ask for both in writing before comparing anything, along with the lot number and whether a batch-specific certificate exists for it.

There is also a supply question underneath the invoice. Because the bulk substance sits on no FDA category list, a clinic sourcing compounded material has no ordinary pharmacy route to it, which means the material came from somewhere else. That is not an accusation, it is the question to ask. The same conversation, applied to a compound where clinics dominate the channel mix entirely, is worked through on our NAD+ channel comparison.

The regulatory record here is short and decisive. Epitalon is absent from the 503A bulks list and from category 1, 2 and 3 on the category lists FDA updated on 14 May 2026. It was nominated for compounding use, placed in category 2 under the interim policies, and then withdrawn by the nominator, which is why the accurate present-tense sentence is that it sits on no list at all rather than that it sits in category 2.

A compounding pharmacy needs a lawful bulk-substance basis before it can compound anything. A substance that has been withdrawn from consideration does not provide one, so this channel is closed before any question of finding a willing prescriber arises. There is no approved product to prescribe either: no FDA approval exists for the compound in any indication.

FDA did publish one substantive statement about it, and it is a testing statement rather than a prohibition. The agency wrote that compounded drugs containing epitalon may pose a risk for immunogenicity for certain routes of administration because of the potential for aggregation and peptide-related impurities, that it has not identified safety-related information for the proposed route, and that it therefore lacks sufficient information to know whether the drug would cause harm if administered to humans. Aggregation and impurities are both measurable, which is exactly why the channel with a purity specification and a contamination screen is the one this page can score.

Marketplace and direct-from-overseas listings almost always show the lowest headline number per vial, and the headline is the only number they show. Four costs sit behind it, none of them printed at checkout.

• Freight and time. Quoted as a flat figure or not at all, with transit measured in weeks rather than days, which matters for a lyophilised powder only in so far as it extends the window in which storage is out of anyone's control.
• Duty and clearance. Applied on arrival rather than at purchase, so the landed cost is not the cart total.
• Loss. A parcel detained or returned is a total loss on that order, which turns the per-milligram figure into a probability-weighted number rather than a price.
• Documentation. Most of these listings publish no batch-linked certificate, which removes the purity, identity and contamination results entirely and leaves nothing to divide except a label weight.

That last one is the real cost. Take away the certificate and you cannot answer the only question FDA raised about the compound, you cannot confirm the sequence, and you cannot confirm the mass. A cheaper vial with no measured content is not cheaper per milligram, it is unpriced.

The final conversion, and the reason a measured fill weight is worth paying for. What follows is laboratory handling arithmetic on a research material and nothing more.

A U-100 syringe is graduated so 100 units equal 1 mL. Add 2 mL of diluent to the vial and the label basis gives 5.00 mg/mL, so the whole vial is 200 units of graduated volume and 10 units is 0.10 mL carrying 500 mcg. On the measured 9.64 mg the same 2 mL gives 4.82 mg/mL, and those 10 units carry 482 mcg.

The third row only exists because somebody weighed the vial. A buyer holding a certificate can add 1.93 mL and put the concentration back where the label implied; a buyer holding only a label cannot, because there is nothing to correct towards. Our Semax channel comparison runs the same conversion at a different price point, and the volume conventions used here are set out in our peptide calculator guide.

Two limits worth carrying away. A certificate covers a sampled aliquot on a date, before filling and transit, so it is evidence about a batch rather than a promise about a vial. And the telomere and longevity claims that make people search for this compound rest largely on work from one research group, so they explain the demand rather than justify it.